Explore more publications!

Colombia Protests Trump’s Drug Trafficking Allegations

(MENAFN) On Tuesday, Colombia’s foreign minister declared that the nation had dispatched a formal letter of protest to the United States after President Donald Trump accused his Colombian counterpart of involvement in narcotics trafficking.

During a press briefing, Rosa Villavicencio explained that she would meet with US charge d’Affaires, John McNamara, to deliver a “(diplomatic) note, rejecting these insults, threats” directed at President Gustavo Petro.

Emphasizing Petro’s legitimacy, she highlighted that “an offence against the president is an offence to our country and a disregard for all the democratic processes that we have carried out.”

Her comments followed Trump’s direct warning to President Petro, in which he accused him of being a drug trafficker.

While speaking to journalists aboard Air Force One, Trump remarked that a possible military action against Colombia “sounds good to me.”

He went further, labeling Colombia a “very sick” nation governed by a “sick man,” and alleged—without evidence—that Petro was engaged in “making cocaine and selling it to the United States.” Trump added that Petro “is not going to be doing it very long.”

President Petro has firmly rejected these accusations, insisting that he has never been involved in drug trafficking.

MENAFN07012026000045017167ID1110566201


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions